Overview

A history of revelationary science

Since Aclaris was founded in 2012, our focus has been innovation to help people with underserved dermatologic conditions, taking inspiration from some of the patients our founders saw in clinical practice as dermatologists.

We're identifying early-stage drug candidates to create novel medicines for skin and hair disorders. We've built a committed, patient-centric organization of nearly 200 employees, guided by leaders with 250+ years of combined experience in developing and commercializing treatments in dermatology and immunology.

Behind the medicine—the founders’ story

Seeking solutions for underserved dermatological conditions since 2012

2012

Aclaris founded

2013

Initiation of clinical program for A-101 40% for seborrheic keratoses

2015

Initial Public Offering

Initiation of clinical program for A-101 45% for common warts

2016

Initiation of phase 3 trials of A-101 40% for raised seborrheic keratoses

Acquisition of intellectual property covering the use of certain Janus kinase inhibitors (JAK) inhibitors for the treatment of alopecia areata, androgenetic alopecia, and other dermatological conditions from Columbia University/Vixen

Initiation of clinical program for oral JAK inhibitor (ATI-501 JAK1/JAK3 Inhibitor) for alopecia totalis and alopecia universalis

2017

Acceptance of new drug application for A-101 40% for seborrheic keratosis

Acquisition of Confluence Life Sciences, Inc.

Initiation of clinical programs for topical JAK inhibitor (ATI-502 JAK1/JAK3 inhibitor) in alopecia areata and vitiligo

FDA approval of ESKATA® (hydrogen peroxide) topical solution, 40% (w/w)

2018

Commercial launch of ESKATA® (hydrogen peroxide) topical solution, 40% (w/w)

Initiation of clinical program for topical JAK inhibitor (ATI-502 JAK1/JAK3 inhibitor) in androgenetic alopecia and atopic dermatitis

Licensing of Canadian rights to commercialize A-101 40% topical solution for the treatment of raised seborrheic keratoses

Aclaris operates Confluence Discovery Technologies, Inc., a full-service drug discovery and early development contract research organization, as an indirect, wholly-owned subsidiary. Confluence serves as a research partner for pharma and biotech companies across therapeutic areas and gene families. Confluence’s expertise includes cell and molecular biology, biochemistry, enzymology, biomarker development, immunology and inflammation, in vivo efficacy models, bioanalytical, computational and medicinal chemistry. To learn more, visit www.confluencediscovery.com.